Company ProfilePremium

Choong Ang Vaccine Laboratory Co., Ltd.

Company Profile Analysis

Ticker: 072020.KQ

ESOMAR 23 Corporate BadgeISO Certifications Badge
Choong Ang Vaccine Laboratory Co., Ltd. - Company showcase

Year Founded & Workforce

1968

194 Employees

Choong Ang Vaccine Laboratory Co., Ltd. logo

Choong Ang Vaccine Laboratory Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Choong Ang Vaccine Laboratory Co., Ltd. Overview

CAVAC is a 58-year-old, family-controlled Korean veterinary biologics specialist. It develops, manufactures and sells vaccines for swine, poultry, dogs, cats, cattle and, from 2027, goats. The company is one of the few Korean-owned firms with an integrated R&D-to-GMP vaccine platform in a domestic market that multinationals (Boehringer Ingelheim, Zoetis, MSD, Ceva and others) have historically dominated with a share of more than 70%. Its franchise brands are SuiShot (swine), FowlShot (poultry), CaniShot and FeliShot (companion animals) and BoviShot (cattle). Revenue was KRW 49.1 bn in FY2025 with an operating margin of about 13%, and the balance sheet holds net cash of about KRW 17 bn. The company has three equity-story pillars. The first is a steady domestic livestock-vaccine business, part of it sold through government procurement. The second is a growing export channel covering 20+ countries, with first-of-kind Korean entries into China and Brazil for Suishot Circo-ONE. The third is optionality from an export-licensed live attenuated African swine fever (ASF) vaccine, SuiShot ASF-X, which is awaiting registration in Vietnam and the Philippines.


What the company does

CAVAC manufactures and sells biological preparations, mainly vaccines, that prevent infectious disease in production animals and companion animals. The company describes itself as a leading developer of animal biological medicines. Its self-description emphasises long accumulated expertise and a range of manufacturing technologies, including toxoid, subunit and recombinant vaccines. Its stated flagship disease areas are classical swine fever, porcine epidemic diarrhoea (PED), highly pathogenic porcine reproductive and respiratory syndrome (HP-PRRS) and low-pathogenic avian influenza (LPAI). The company is also developing user-friendly delivery formats, including needle-free, drinking-water, oral and spray administration (company overview as summarised by ValueLine from the business report).

Business and revenue model

The revenue model is almost entirely product sales: finished vaccine vials or doses sold per batch after national lot-release approval from the Animal and Plant Quarantine Agency (APQA). Three secondary streams sit alongside it:

  1. Contracted services (용역): contract research, disease testing and biologics studies. About 4% of revenue in Q2 2026 (Butler, citing the business report product mix).

  2. Government procurement and distribution: supply under Public Procurement Service (PPS) tenders. This includes vaccines CAVAC makes and, since 2026, vaccines it imports and distributes. An example is a KRW 5.81 bn SAT1 foot-and-mouth disease (FMD) vaccine contract signed 8 July 2026. CAVAC said it would import that volume from overseas manufacturers (Edaily, 8–9 July 2026).

  3. Licensing and distribution partnerships abroad: for example, an exclusive distribution agreement under which Elanco China sells Suishot Circo-ONE. The contract terms are not publicly disclosed.

CAVAC has no subscription or royalty income of any significance that has been disclosed.

Sales channels

The most recent channel split found is from the 2019 NICE technology analysis report, using FY2018 data. That year, sales through dealers and agents were 44.2% of revenue, government supply through the PPS was 26.3%, and exports were 27.2%. Management has stated a long-term ambition to raise exports to 60% of revenue (BioBook Media, August 2026).

Customers and end-markets

End-marketCustomer typeNotes
Swine production (Korea and export)Integrated pig producers, farm veterinarians, dealers; overseas distributors (Elanco China; partners in Brazil, Thailand, Vietnam)Largest product family; about 50% of Q2 2026 revenue
Poultry (broilers, layers, breeders)Integrators (for example Harim, a development partner), hatcheries, layer farmsAbout 28% of Q2 2026 revenue
Companion animals (dogs, cats)Veterinary clinics via distributorsAbout 11% of Q2 2026 revenue
Cattle and small ruminantsBeef and dairy farms; goat farms from 2027Cattle about 4% of Q2 2026 revenue
Government animal-disease controlMAFRA via PPSEmergency and stockpile tenders, such as SAT1 FMD in 2026
Contract servicesGovernment, academia, industryAbout 4%

Value-chain position

CAVAC is vertically integrated across seed-strain development, antigen production (cell culture and bioreactors), formulation (including its proprietary adjuvant CAvant), filling, freeze-drying, labelling and quality control under KVGMP. Production takes place at Plant 1 in Daejeon and at Plant 2 in Nonsan, which handles poultry vaccines and animal testing. For live ASF virus, Korean rules require BL3 containment. CAVAC has no such facility, so its ASF vaccine was licensed on a contract-manufacturing basis at a GMP site in Hanoi, Vietnam (DailyVet, April 2026).

Independent characterisation

CAVAC is best understood as a niche, cash-generative biologics manufacturer with embedded R&D optionality. Its core domestic business grows in the mid-single digits and is exposed to livestock cycles and disease outbreaks. It is profitable (operating margin 11–17% over FY2021–FY2025), heavily capitalised relative to revenue (equity of KRW 105 bn against revenue of KRW 49 bn) and conservatively financed. Inventory intensity is a structural feature of vaccine manufacturing: work-in-progress and semi-finished antigen are held for long periods. Inventory reached KRW 22.0 bn at end-FY2025, or about 45% of annual revenue. The market values CAVAC below book value (P/B about 0.77×), which suggests investors are not paying for the ASF or FMD options.

Strategy

Stated strategic themes

Company materials and the business report emphasise the following themes, paraphrased:

Vision: to be a "Global Bio Leader" that pursues animal health and human well-being (company deck).

Global network: expand exports through a worldwide distribution network, and win more overseas product registrations by strengthening GMP standards.

R&D-led portfolio renewal: bring vaccines matched to locally circulating strains to market quickly, such as Y280 LPAI, the PED G2b variant and Korean swine influenza subtypes.

User convenience: develop needle-free, water-delivered, oral and spray administration.

Government partnership: take part in national disease-control programmes and procurement.

Initiatives announced in the last 24 months

DateInitiativeDescription and strategic intent
6 Aug 2025Harim poultry-disease MOUHarim monitors respiratory disease on its contract farms and supplies IB field isolates and data; CAVAC develops variant-matched IB vaccines
Sep 2025ASF bait vaccine research in VietnamExtends the ASF platform to wild boar, an area of European interest
Oct–Dec 2025Shareholder-return programmeKRW 1.0 bn buyback (decided 30 Oct 2025; 101,906 shares bought between 3 Nov 2025 and 30 Jan 2026, 97.7% of the plan); KRW 2.0 bn treasury-share cancellation (10 Dec 2025)
Feb 2026FowlShot ND Max launchLarge-pack product for large broiler integrators
25 Feb 2026ASF vaccine results presentationTargets commercialisation in 2027; calls for a national expert consultative body on ASF vaccine use in Korea
25 Mar 2026Corporate value-up plan disclosureDiscloses "high-dividend company" status under the Restriction of Special Taxation Act, so eligible shareholders can opt for separate dividend taxation.
15 Apr 2026SuiShot ASF-X export licencePath to registration and sales in Vietnam and the Philippines
Apr 2026K-FMD clinical trial with OptipharmDomestic FMD vaccine sovereignty and non-BL3 manufacturing
Jun 2026IPVS 2026 satellite symposiumInternational positioning of ASF-X
25 Jun 2026CapriShot CLA licence; KRW 2.1 bn share cancellationEnters the goat segment, in line with MAFRA's February 2026 Goat Industry Development Plan
8 Jul 2026SAT1 FMD vaccine supply to PPSBuilds the procurement and distribution business; CAVAC says it will expand vaccine supply work as disease-control needs change
Undated (2025–26)Daejeon companion-animal industry agreementAgreement with Daejeon City, Chungnam National University and O-World to grow the local pet industry

Medium-term targets and guidance

TargetTimingSource
Raise exports to 60% of revenueNo dateBioBook Media (Aug 2026)
Commercialise the ASF vaccine (Vietnam and the Philippines first)2,027DailyVet (Feb 2026)
K-FMD product licence and launchLicence 2026; launch 2027DailyVet (Apr 2026)
CapriShot CLA launchH1 2027DailyVet (Jul 2026)

CAVAC gives no formal financial guidance. The following non-financial targets have been disclosed:

ESG commitments and cost-reduction programmes with quantified targets are not publicly disclosed.

Products & Services

Portfolio size is reported differently across years: "over 80 products" (DailyVet, 2020–2021), "about 70 products" (eToday, 2023) and an export lineup of "85+ products" (BioBook Media, 2026). The differences probably reflect whether product counts, registrations or SKUs are being counted. Pricing is not publicly disclosed for any product. Livestock vaccines are generally sold per vial or per dose through dealers or tenders.

Swine — SuiShot® brand

ProductDescription and capabilitiesTarget customerLaunch / statusNotes
SuiShot® Circo-ONEPorcine circovirus type 2 (PCV2) vaccine preventing PCV-associated disease (PCVAD)Pig farms in Korea, China, Brazil and elsewhereRegistered in China Oct 2023 (first Korean animal vaccine there); Brazil shipments from Apr 2024; China shipments from Oct 2024Distributed in China by Elanco China under an exclusive agreement
SuiShot® PED-XInactivated vaccine against the G2b variant of PED virus, which spread across Korea from 2014Breeding herds (sows)2015; described as Korea's first G2b inactivated vaccineDescribed as a top PED product and a leading export earner (eToday 2023)
SuiShot® PED-X LiveOral live second-generation PED vaccine; the company called it a world firstBreeding herdsHighlighted at the 2020 IHS Markit award—
SuiShot® CSFV Marker-LClassical swine fever live marker vaccine (supports differentiating infected from vaccinated animals)Pig farmsHighlighted 2020—
SuiShot® Flu-3Trivalent swine influenza vaccine covering the Korean field subtypes H1N1, H1N2 and H3N2Pig farmsPromoted at the 2025 "SuiShot Re:Booster Day" seminarPositioned for locally circulating strains
SuiShot® ASF-XLive attenuated ASF vaccine based on strain ASFV-MEC-01, isolated from a Korean wild boar and attenuated. Genotype II protection. Labelled for sows, gilts and piglets (two intramuscular doses given three weeks apart)ASF-endemic markets (Vietnam, Philippines first)Export-only licence 15 Apr 2026; registration under way in Vietnam and the Philippines; commercialisation target 2027Contract-manufactured in Hanoi. The company says it is the first commercial ASF vaccine with sow and gilt claims
HP-PRRS vaccineVaccine against highly pathogenic PRRSPig farmsListed as a flagship area in the company overview—
ASF oral bait vaccine (pipeline)Oral bait formulation for wild boarWildlife authorities (European interest noted)Research in Vietnam (DailyVet, Sep 2025)Pre-commercial

Poultry — FowlShot® brand

ProductDescription and capabilitiesTarget customerLaunch / statusNotes
FowlShot® Flu-Y280Inactivated LPAI H9N2 vaccine using the Y280-lineage strain that APQA developed from a 2021 Hwasun isolate and transferred to industryLayers, breeders, broilersEarly 2023; first Y280 vaccine on the marketAddresses Y280 strains against which older Y439 vaccines gave poor protection
FowlShot® 5280 ABBNEFive-way inactivated combination: Y280 LPAI + two nephropathogenic IB strains (QX and KM91) + Newcastle disease (ND) + egg drop syndrome (EDS); uses the CAvant® adjuvantLayers and breedersNational lot release 19 Oct 2023Reduces the number of injections per flock
FowlShot® 4280 ABBNFour-way combination: Y280 LPAI + IB (QX, KM91) + ND; CAvant® adjuvantLayers and breedersLaunched 1 Feb 2024Line extension
FowlShot® Adeno trivalentTrivalent vaccine against fowl adenovirus serotypes 4, 8b and 11Broiler breedersDeveloped Apr 2023; launch seminar 26 Jul 2023Responds to limited cross-protection between serotypes
FowlShot® ND MaxLarge-pack (5,000-dose) enterotropic ND live vaccineLarge broiler operationsLaunched Feb 2026Enterotropic strain designed for short respiratory persistence
FowlShot® IB rangeIB vaccines positioned against the emerging K-IId QX-type IB virusPoultry integratorsTrade-press feature Jul 2026A Harim co-development pipeline (2025 MOU) targets variant IB strains
Earlier AI vaccineAvian influenza vaccinePoultryDeveloped Dec 2006, sold from Feb 2007Historical

Companion animals

Product lineDescriptionTarget customerStatus
CaniShot®Canine vaccinesVeterinary clinicsActive; about 11% of revenue in Q2 2026
FeliShot®Feline vaccinesVeterinary clinicsActive; share not separately disclosed

Ruminants and other species

Product lineDescriptionTarget customerStatus
BoviShot®Cattle vaccinesBeef and dairy farmsActive; about 4% of revenue
CapriShot® Caseous LymphadenitisInactivated vaccine against Corynebacterium pseudotuberculosis combining whole-cell bacterin and toxoid; Korea's first licensed CLA vaccine for goatsGoat farmsLicensed 25 Jun 2026; launch planned for H1 2027
Fish and rabbit vaccinesMentioned in the company's English profileAquaculture, rabbit producers—

Platforms, technology and services

OfferingDescription
CAvant® adjuvantProprietary immune-enhancing adjuvant used in FowlShot combination vaccines
Manufacturing technology baseToxoid, subunit and recombinant vaccine manufacturing; bioreactors; freeze-drying; automated vial filling and packaging (KVGMP)
Contract servicesBiologics research and disease testing services (about 4% of revenue)
Import and distributionSAT1 FMD vaccine imported and supplied to the government under the July 2026 PPS contract
K-FMD vaccine (pipeline)Nanoparticle-based FMD vaccine. Optipharm developed the master seed and CAVAC produces the clinical-trial material. The vaccine can be made in a standard (non-BL3) facility. Six-month field trial on six cattle and pig farms; target of licensing in 2026 and launch in 2027 (DailyVet, Apr 2026)

Financial Narrative

All figures are K-IFRS standalone, KRW bn unless stated. Main sources are DART business reports as aggregated by ETF Shopping and Butler (revenue, operating income, net income for FY2021–FY2025), the FY2024 AGM results filing, and ValueLine (detailed line items for the balance sheet FY2022–FY2025, and income-statement and cash-flow detail for FY2025). Some aggregator figures differ slightly from audited figures because of rounding. For example, FY2024 operating income is 5.8 in the aggregators against 5.758 in the AGM filing.

Income statement

Margins are derived. FY2024 operating and net income come from the 25 Mar 2025 AGM filing (KRW 5,758m and KRW 6,850m). FY2025 operating and net income come from ValueLine line items (KRW 6.47 bn and KRW 6.15 bn). Kormedi, citing the year-end disclosure, rounds these to KRW 6.5 bn and KRW 6.2 bn.

Revenue CAGR for FY2021–FY2025 was 4.7%. For FY2023–FY2025 it was 8.3%. Both are derived. BioBook Media separately reports that the company described growth of 8% or more a year over 2023–2025.

FY2025 detailed income statement (ValueLine, standalone):

Diluted EPS equals basic EPS because no dilutive instruments are disclosed.

EPS (basic, KRW):

The FY2024 figure comes from the AGM filing and the FY2025 figure from ValueLine.

Commentary. Revenue fell in FY2022 (-3.9%), the only decline in the window. It then grew for three consecutive years, driven by new poultry products (the Y280 LPAI combinations from 2023), PCV2 export entries (Brazil and China from 2024) and price and mix. Operating margin peaked at 16.7% in FY2023. It fell to 12.6% in FY2024 as payroll costs rose: average pay jumped from KRW 38.3m to KRW 51.0m per head, and payroll intensity went from 16.3% to 20.9% of revenue (ETF Shopping). FY2025 brought partial recovery to 13.2%. Net income has run above operating income in most years. Interest income on a sizeable cash and deposit pile and foreign-exchange gains on export receivables explain the gap.

Interim and trailing results

Q3 2025 comes from Edaily (Nov 2025). Q2 2026 comes from Kormedi, citing the preliminary results disclosure of 5 Aug 2026. Q1 2026 is derived as H1 2026 minus Q2 2026.

H1 2026 revenue was down 3.1% year on year, while operating income rose 9.3% and net income 65.6% (Kormedi, citing the disclosure). In Q2 2026, revenue fell 1.2% and operating income fell 23.8% year on year, yet net income rose 90.4%. BioBook Media attributes the gap mainly to non-operating gains, including foreign-exchange gains on export business.

On a trailing twelve-month basis to June 2026 (ValueLine), revenue was KRW 48.27 bn, operating income KRW 6.83 bn, EBITDA KRW 14.60 bn and net income KRW 7.98 bn (EPS KRW 838).

Balance sheet

Total borrowings, net debt and working capital are derived. Net debt is borrowings minus cash and short-term financial instruments; lease liabilities (about KRW 0.1–0.3 bn) are excluded. Working capital is current assets minus current liabilities.

At 30 June 2026, total assets were KRW 125.51 bn, inventories KRW 24.99 bn, cash plus short-term instruments KRW 26.93 bn, borrowings KRW 6.17 bn and equity KRW 108.11 bn (BPS KRW 11,430).

Commentary. The balance sheet has de-risked steadily. Short-term borrowings of KRW 6.4 bn at end-FY2022 were repaid, total borrowings fell by 44% between FY2022 and FY2025, and net cash grew from KRW 3.6 bn to KRW 17.2 bn. PP&E stays near KRW 63–67 bn, reflecting the Nonsan Plant 2 investment completed around 2021, and it makes up about half of total assets. This is a capital-heavy footprint for a KRW 49 bn revenue base, and it holds down asset turnover. The clearest recent change is inventory, which rose 24% in FY2025 to KRW 22.0 bn and then to KRW 25.0 bn by June 2026. In FY2024 semi-finished goods (KRW 9.5 bn at FY2025) were reclassified out of work-in-progress, so movements within inventory categories need care. Plausible drivers include stock-building for export launches and longer production cycles; the SAT1 FMD imports, which began in July 2026, could explain only the post-June build.

Cash flow

Source: ValueLine, FY2025 column. The aggregator's free-cash-flow definition is narrower than OCF minus PP&E capex.

On a trailing twelve-month basis to June 2026, operating cash flow was KRW 11.37 bn, PP&E capex KRW 5.60 bn and free cash flow (ValueLine definition) KRW 3.69 bn.

Shareholder cash returns, FY2021–FY2025 (ETF Shopping from DART; buybacks on a cash-flow-statement purchase basis):

Commentary. FY2025 operating cash flow (KRW 7.9 bn) was below FY2025 EBITDA (KRW 12.5 bn). About KRW 5.9 bn was absorbed by working capital, mostly inventory (KRW -4.2 bn), along with severance and pension payments. With capex of about KRW 5.9 bn, near maintenance level against KRW 6.2 bn of depreciation, free cash flow was roughly breakeven. Even so, the company paid out KRW 4.9 bn in dividends and buybacks and repaid debt, drawing on its deposits. Cash generation improved in H1 2026 (TTM OCF KRW 11.4 bn) as receivables were collected.

Ratios

All ratios are derived from the figures above.

ValueLine reports a five-year average ROE of 6.10% and a TTM ROE of 7.39%.

Commentary. Returns are modest: ROE of 6–7% sits well below Korea's typical cost of equity. The reason is not weak margins but excess capital: KRW 24 bn of cash and deposits against KRW 105 bn of equity, plus low asset turnover. The cash conversion cycle of nearly a year is structurally long. Vaccine antigen and semi-finished goods carry long QC and lot-release lead times, and the business pays suppliers quickly. Inventory discipline is therefore the most important operating lever for cash generation. Leverage risk is negligible.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Product Families

Product familyShare of revenue, Q2 2026 (%)

Swine vaccines (SuiShot)

50

Poultry vaccines (FowlShot)

28

Canine vaccines (CaniShot)

11

Services (contract research and testing)

4

Cattle vaccines (BoviShot)

4

Other (feline, other species, merchandise; residual)

3

Investee Details

InvesteeCAVAC stake (%)Investee total assets (KRW Bn)Investee net income (KRW Bn)Nature

GPI CAVAC Biologicals, LLC

102.27-0.016—

Avinext Co., Ltd. (㈜아비넥스트)

121.450.15

ASF vaccine co-developer (ASFV-MEC-01 consortium)

Hansu Pharm Co., Ltd. (㈜한수약품)

21.710.044

Veterinary pharmaceutical company run by the Korean Veterinary Medical Association

Korea Animal Medicine Industrial Cooperative

—1.870.010

Industry cooperative membership

“—” = not publicly disclosed.

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

40.939.341.945.649.1

Revenue growth (%)

12.7-3.96.58.97.6

Operating income (KRW Bn)

4.54.37.05.766.47

Net income (KRW Bn)

7.64.06.06.856.15

Operating margin (%)

11.010.916.712.613.2

Net margin (%)

18.610.214.315.012.5

Dividend per share (KRW)

100100150170200

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Analysis

Line item (FY2025)KRW Bn% of revenue (derived)

Revenue

49.06100.0

Cost of sales

25.1851.3

Gross profit

23.8848.7

SG&A

17.4035.5

of which R&D expense

2.244.6

of which salaries

5.9812.2

of which fees and commissions

2.785.7

Operating income

6.4713.2

EBITDA (ValueLine definition)

12.4925.5

Net financial income

0.200.4

Other non-operating, net

-0.12-0.2

Pre-tax income

6.5513.4

Income tax

0.390.8

Net income

6.1512.5

Basic EPS (KRW)

638—

Per-Share Data

MetricFY2024FY2025

Basic EPS (KRW)

713638

Income Statement

MetricQ3 2025Q1 2026Q2 2026

Revenue (KRW Bn)

10.9812.5911.90

Operating income (KRW Bn)

1.553.001.14

Net income (KRW Bn)

—3.331.29

Income Statement (Half-Yearly)

MetricH1 2025H1 2026

Revenue (KRW Bn)

25.2924.50

Operating income (KRW Bn)

3.794.14

Net income (KRW Bn)

2.794.62

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025

Total assets (KRW Bn)

114.85119.59123.27122.81

Current assets (KRW Bn)

39.5950.5652.4551.61

Cash and equivalents (KRW Bn)

7.8414.3813.4610.47

Short-term financial instruments (KRW Bn)

7.9112.7715.4013.55

Trade receivables (KRW Bn)

3.214.194.794.37

Inventories (KRW Bn)

17.9118.4617.6922.02

Property, plant and equipment (KRW Bn)

66.6462.8364.0863.66

Intangible assets (KRW Bn)

0.430.531.061.08

Goodwill (KRW Bn)

0000

Current liabilities (KRW Bn)

13.3112.6512.0112.09

Short-term borrowings (KRW Bn)

6.42000

Current portion of long-term debt (KRW Bn)

04.091.692.00

Long-term borrowings (KRW Bn)

5.786.536.844.84

Total borrowings (KRW Bn)

12.2010.628.536.84

Net debt (KRW Bn; negative = net cash)

-3.55-16.53-20.33-17.18

Total liabilities (KRW Bn)

19.5519.7819.4017.44

Shareholders' equity (KRW Bn)

95.3099.80103.86105.36

Working capital (KRW Bn)

26.2837.9140.4439.52

Book value per share (KRW)

9,56910,33310,75411,140

Cash Flow

MetricFY2025

Operating cash flow (KRW Bn)

7.87

Capital expenditure, PP&E (KRW Bn)

5.91

Capital expenditure, intangibles (KRW Bn)

0.05

Free cash flow, ValueLine definition (KRW Bn)

-0.04

Depreciation, PP&E (KRW Bn)

6.17

Dividends paid (KRW Bn)

1.62

Treasury-share purchases (KRW Bn)

3.00

Long-term debt repaid (KRW Bn)

1.69

Dividends & Capital Returns and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025

Dividends declared (KRW Bn)

1.01.01.41.61.9

Treasury share purchases (KRW Bn)

1.61.00.11.13.0

Total shareholder return (KRW Bn)

2.62.01.52.74.9

Dividend payout ratio (%)

1324242430

Total payout ratio (%)

3450263979

Margin Analysis (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE, net income / year-end equity (%)

4.26.06.65.8

ROA, net income / year-end assets (%)

3.55.05.65.0

Current ratio (x)

2.974.004.374.27

Debt to equity (%)

12.810.68.26.5

Liabilities to equity (%)

20.519.818.716.6

Asset turnover (x)

0.340.350.370.40

Financial Analysis — ROIC

Ratio (FY2025)ValueBasis

ROIC (%)

6.9

NOPAT (operating income × (1 – 6% effective tax rate)) ÷ (equity + debt – cash and short-term instruments); derived

Net debt / EBITDA (x)

-1.4

Net cash position; derived

Interest coverage (x)

30.8

Operating income ÷ interest expense of KRW 0.21 bn; derived

EBITDA margin (%)

25.5

ValueLine

Days sales outstanding

33

Year-end trade receivables ÷ revenue × 365; derived

Days inventory outstanding

319

Year-end inventory ÷ cost of sales × 365; derived

Days payables outstanding

8

Year-end trade payables (KRW 0.58 bn) ÷ cost of sales × 365; derived

Cash conversion cycle (days)

about 344

Derived; year-end balances, not averages

Revenue by Region (%)

MetricFY2016FY2018

Export share of revenue (%)

1327.2

Region Overview

RegionDisclosed marketsStatus and evidence

Southeast Asia

Thailand, Vietnam (named as main export markets, 2023), Philippines, Cambodia, Indonesia, Myanmar

Core export region; site of ASF-X field trials and the registration pipeline

Greater China

China

Circo-ONE registered Oct 2023; Elanco China exclusive distribution; first shipments Oct 2024

Latin America

Brazil (Circo-ONE from Apr 2024), Mexico

Brazil described by the company as a very large new market

Middle East

Bahrain, UAE, Jordan

Listed export destinations (PR Newswire, 2021)

South Asia

India, Pakistan

Listed export destinations

Africa

Nigeria, Egypt

Listed export destinations

CIS

Russia

Listed export destination (2021)

Domestic (Korea)

Nationwide via dealers, PPS and veterinary distributors

Largest revenue base

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

11,00011,0109,8009,800

Year-end market capitalisation (KRW Bn)

109.6109.794.794.7

Shares outstanding (millions)

9.969.669.669.46

Capital Markets

ItemValueSource

Close, 19 Oct 2026

KRW 9,110 (+1.22% on the day)

ValueLine

Market capitalisation

About KRW 83.3 bn

ValueLine

52-week range

KRW 8,560 – 10,350

StockHub

6-month change

-8.16%

ValueLine

Change from end-FY2025

-7.0% (derived)

—

Change from end-FY2022

-17.2% (derived; excludes dividends)

—

Valuation Multiples

MultipleCAVAC currentCAVAC 5-year average

P/E, TTM (x)

10.4320.47

P/B (x)

0.771.09

EV/EBITDA (x)

4.288.16

P/S (x)

1.732.53

Dividend yield (%)

2.2—

Per-Share Data (FY2016–FY2025)

MetricFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Dividend per share (KRW)

5050505070100100150170200

Analyst Conclusions

Management guidance and consensus

No formal financial guidance and no consensus forecasts exist. In July 2026 management said the SAT1 contract would help FY2026 results. The contract adds up to KRW 5.81 bn of revenue across July–November 2026. Because the product is imported, the margin on this distribution revenue is likely lower than on CAVAC-manufactured vaccines, but the contract's gross margin is not disclosed. Q3 2026 preliminary results are expected in early November 2026, based on the usual timing of the first week of November.

Bull case

  1. ASF-X becomes a step-change product. If registrations in Vietnam and the Philippines arrive and the sow and gilt claim holds up, the FY2025 base of about KRW 30 bn in swine-related revenue could be supplemented materially. Even a small share of Southeast Asia's endemic ASF markets would be large relative to KRW 49 bn of total revenue.

  2. Valuation already offers downside support. At 0.77× book, 4.3× EV/EBITDA, a 2.2% yield and a 79% FY2025 total payout, investors pay little or nothing for the pipeline. Net cash covers about 25% of market capitalisation.

  3. More pipeline shots and domestic tailwinds. K-FMD (licence targeted for 2026) addresses a market where Korea currently imports all its FMD vaccine. The goat CLA launch and Harim IB development add growth, and government support for vaccine sovereignty (BL3 access, procurement) is strengthening.

Bear case

  1. The core business is stagnating. H1 2026 revenue fell 3.1% and Q2 operating income fell 23.8%. The jump in net income came from non-operating gains, which are low quality. Payroll intensity is rising.

  2. ASF commercial risk is high. CAVAC has no BL3 facility of its own. Komipharm has a parallel licence and BL3 access. Vietnam already has licensed local incumbents. WOAH has publicly voiced caution about live ASF vaccines. Timelines have already moved: the 2025 strain-establishment goal was followed by a 2027 commercialisation target.

  3. Capital efficiency and cash conversion are poor. ROE is about 6%, inventory is rising, the cash cycle is about 344 days and FY2025 FCF was about breakeven. Governance is concentrated in the controlling family. Without operating improvement, the discount to book may persist.

Catalysts and monitorables for the next 12 months

Catalyst / monitorableExpected timingWhat to watch
Q3 2026 preliminary resultsEarly Nov 2026Revenue contribution from SAT1; operating margin recovery; inventory
Completion of SAT1 contract7 Nov 2026Full recognition of KRW 5.81 bn; follow-on tenders
ASF-X registration in Vietnam and/or the PhilippinesH2 2026 – 2027Approval dates; label claims; manufacturing partner capacity; pricing
K-FMD licence decisionLate 2026 – 2027Clinical neutralising-antibody results; procurement eligibility
FY2026 dividend and buyback decisionsFeb 2027Whether DPS rises for a fourth year; payout above 30%
CapriShot CLA launchH1 2027Uptake; competition from Woogene B&G
Inventory and FCF in FY2026 annual reportMar 2027Reversal of the inventory build
Korean policy on domestic ASF vaccine useOngoingAny move from export-only to domestic authorisation

Analyst verdict

CAVAC is a well-run, conservatively financed niche producer whose share price embeds almost no value for its development pipeline. Over FY2021–FY2025 it compounded revenue at 4.7% a year, kept operating margins in the low-to-mid teens, paid down most of its debt, and doubled its dividend per share while cancelling shares. Those traits explain why the stock trades at 0.77× book and about 4× EV/EBITDA. The market has not rewarded capital that is earning only about 6% returns, held back by surplus cash, a heavy fixed-asset base and inventory that now equals almost half a year's revenue.

The case therefore depends on whether the pipeline turns from licences into revenue. The April 2026 export licence for SuiShot ASF-X is a genuine milestone. Korea became only the second country to license an ASF vaccine, and the sow-and-gilt label differentiates CAVAC's product. Even so, the path to revenue runs through foreign registrations, a Vietnamese contract manufacturer and a competitive field that includes Komipharm, Vietnam's AVAC and Navetco, and multinational entrants. K-FMD and the goat CLA vaccine are credible but smaller options. In the near term the core business needs to show it can grow again: H1 2026 revenue declined, Q2 operating profit contracted sharply, and headline net profit was flattered by currency gains.

On balance, CAVAC fits a patient, value-oriented investor who is comfortable with illiquidity and a controlling family. The downside is cushioned by net cash, a dividend yield above 2% and a payout policy that has improved for three straight years. The upside depends on events: an ASF-X registration in Vietnam or the Philippines would be the clearest re-rating trigger. The main things to watch over the next year are Q3 2026 operating margins, the inventory trajectory, ASF-X registration news and the FY2026 capital-return decision. Absent progress on these, the valuation discount is likely to persist.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenureBackground and educationAge / born

Dr. Yoon In-jung (윤인중)

Chairman and Representative Director

CEO since 1999; re-elected inside director 25 Mar 2025 for 3 years

DVM Konkuk University; MS Veterinary Medicine Seoul National University; PhD Veterinary Medicine University of Minnesota. Son of the founder

Born Aug 1962 (age 64)

Yoon Seok-in (윤석인)

Representative Director (independent co-representative structure)

—

Related party of the largest shareholder; holds 7.58%.

—

Dr. Lee Ju-yong (이주용, "Jason Lee")

President; inside director

Formerly Vice President; re-elected inside director 25 Mar 2025 for 3 years

DVM and MS Veterinary Medicine Seoul National University; MBA Maastricht School of Management. Called CEO in international trade press

Born Nov 1973 (age 52)

Dr. Yoo Sung-sik (유성식)

Head of Overseas Business; head of the ASF project; registered director

—

Presented ASF-X data at IPVS 2026 and at the Feb 2026 results presentation

—

Founder: Dr. Yoon Ji-byung (윤지병)

Founder (deceased 1999)

1968–1999

Seoul National University veterinary graduate (1958); government Animal Health Research Institute

1934–1999

“—” = not publicly disclosed.

Board & Management Changes

DateEvent

25 Mar 2025

Yoon In-jung and Lee Ju-yong re-elected as inside directors

Major Shareholders

HolderRelationshipStake at 31 Dec 2025 (%)

Yoon In-jung

Largest shareholder

24.32

Yoon Seok-in

Related party

7.58

Kim Eun-hee

Related party

1.97

Yoon Seok-won

Related party

0.28

Kim Pil-bong

Related party

0.18

Lee Han-san

Related party

0.15

Lee Han-cheol

Related party

0.13

Yoon Hee

Related party

0.13

Kim Hyo-jin

Related party

0.12

Lee Han-rim

Related party

0.11

Yoo Sung-sik

Registered officer

0.01

Lee Ju-yong

Registered officer

0.01

Largest shareholder and related parties, total

—34.99

Minority shareholders (11,071 holders)

—58.8

Treasury shares (approximate, Butler)

—2.13

Competitive Landscape

Key Competitors

CompetitorTypeOverlap with CAVACRelative positioning

Boehringer Ingelheim Animal Health

Multinational

Swine (PCV2, PRRS), poultry, companion

Global #3; animal health revenue USD 4.94 bn (2024, PharmaShots). Strong position in Korean swine biologics

Zoetis

Multinational

All species

Global #1; revenue USD 9.25 bn (2024, PharmaShots)

MSD Animal Health (Merck)

Multinational

Swine, poultry, companion; ASF vaccine development presented at IPVS 2026

Global #2; revenue USD 5.87 bn (2024, PharmaShots)

Elanco

Multinational

Companion, poultry. Also CAVAC's distribution partner in China

Competitor and partner

Ceva Santé Animale

Multinational

Poultry vaccines, swine

—

Komipharm (KOSDAQ)

Korean

ASF vaccine (Pro-Vac ASF, export licence 16 Apr 2026); PED vaccine (China approval Feb 2025)

Most direct domestic rival in ASF; first user of the APQA BL3 suite

Daesung Microbiological Labs (대성미생물연구소, KOSDAQ)

Korean

Vaccines, antibiotics, feed additives (about 150 products)

Broader, lower-concentration portfolio; KVGMP plant expansion; exports 26% of revenue in its latest reported period

Green Cross Veterinary Products (녹십자수의약품)

Korean

Swine and poultry vaccines; PCV technology tie-up with Optipharm (2023)

Domestic competitor in swine biologics

Optipharm (KOSDAQ)

Korean

Diagnostics, vaccines; K-FMD partner

Partner in FMD; competitor in some swine vaccines

Woogene B&G (우진비앤지, KOSDAQ)

Korean

Veterinary drugs, fish vaccines; goat CLA vaccine patent

Head-to-head in goat CLA from 2027

Eagle Vet (이글벳, KOSDAQ)

Korean

Veterinary drugs, pet food distribution

Overlaps mainly in companion-animal channels

FVC (에프브이씨)

Korean

Domestic inactivated FMD vaccine (APQA technology transfer due by end-2026)

Competitor to the K-FMD programme

Careside

Korean

ASF vaccine candidate (with Spain's CSIC)

ASF pipeline competitor

AVAC Vietnam JSC; Navetco

Vietnamese

Licensed ASF live vaccines (AVAC licensed since Jul 2023)

Incumbents in the first ASF-X target market. WOAH raised concerns about data sharing for AVAC (Reuters via Tribune India)

Peer Comparison FY2025

MetricCAVACZoetisMSD Animal HealthBoehringer Ingelheim AH

Revenue

KRW 49.1 bn (FY2025), about USD 0.035 bn

USD 9.25 bn (2024)

USD 5.87 bn (2024)

USD 4.94 bn (2024)

Revenue growth (%)

7.6 (FY2025)

———

Operating margin (%)

13.2 (FY2025)

—

Not reported separately at segment level in sources reviewed

—

R&D intensity (%)

4.6 (SG&A-expensed, FY2025); management cites about 10%

———

Company Snapshot

$34.6M

Revenue

194

Employees

1968

Founded

Daejeon, South Korea

Headquarters

SWOT Analysis

Strengths

  • Fortress balance sheet. Net cash of KRW 17.2 bn and a debt-to-equity ratio of 6.5% at FY2025; interest coverage of about 31× (derived, Section 6).
  • Consistent profitability. Operating margin stayed between 10.9% and 16.7% in every year from FY2021 to FY2025, with a FY2025 EBITDA margin of 25.5% (ValueLine).
  • First-of-kind regulatory wins. First Korean animal vaccine registered in China (Circo-ONE, Oct 2023); first Y280 LPAI vaccine (2023); ASF export licence (Apr 2026); first goat CLA vaccine licence (Jun 2026).
  • Multinational distribution validation. Elanco China holds exclusive rights to Circo-ONE (DailyVet, 2024).
  • Growing shareholder returns. DPS rose from KRW 100 to KRW 200 between FY2021 and FY2025; the FY2025 total payout ratio was 79%; KRW 4.1 bn of shares were cancelled in 2025–26.
  • Government-partnership depth. Recurring PPS contracts (a KRW 5.81 bn SAT1 award in July 2026) and access to state-developed strains such as Y280.

Weaknesses

  • Low returns on capital. ROE of 5.8% and ROIC of about 6.9% in FY2025 (derived), held down by excess cash and PP&E of KRW 63.7 bn.
  • Very long cash cycle. Days inventory outstanding of about 319 days; inventory up 24% to KRW 22.0 bn in FY2025; FY2025 free cash flow about breakeven (ValueLine).
  • Small scale. FY2025 revenue of KRW 49.1 bn is about 0.4% of Zoetis's 2024 revenue.
  • No in-house BL3 facility, so ASF-X production depends on a Vietnamese contract manufacturer (DailyVet, Apr 2026).
  • Rising fixed costs. Payroll rose from 16.3% of revenue in FY2023 to 22.4% in FY2025 (ETF Shopping).
  • Thin disclosure and liquidity. No analyst coverage; a liquidity provider contract signed in August 2026; no English-language reporting.

Opportunities

  • ASF-X registration in Vietnam and the Philippines, which the company expected "over the next few months" in June 2026, and commercialisation targeted for 2027.
  • K-FMD vaccine. Korea currently imports all its FMD vaccines; the target is a licence in 2026 and launch in 2027 (DailyVet, Apr 2026).
  • Scaling exports toward the 60% target through China and Brazil.
  • The goat segment supported by MAFRA's February 2026 Goat Industry Development Plan, with launch in H1 2027.
  • Variant-matched poultry vaccines with Harim for IB.
  • Government BL3 capacity (pilot from June 2026; dedicated private BL3 by 2030) could eventually allow production of ASF vaccines in Korea.

Threats

  • Domestic ASF competition. Komipharm received an export licence one day after CAVAC (16 Apr 2026) and has BL3 access.
  • Incumbent Vietnamese ASF vaccines (AVAC, licensed since July 2023; Navetco) and MSD's ASF programme (IPVS 2026).
  • Regulatory scepticism toward live ASF vaccines. WOAH has publicly warned about risks and data-sharing gaps for Vietnamese ASF vaccines (Reuters).
  • Dominant multinationals with more than 70% of the domestic market (2016).
  • Livestock disease shocks that shrink herds, or a policy change that cuts procurement.
  • Currency swings. H1 2026 net income was inflated by foreign-exchange gains, which can reverse.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2025 (seminar)"2025 SuiShot Re:Booster Day" seminar in Daejeon promoting SuiShot Flu-3Marketing push for the swine influenza line
2 May 2025Q1 2025 preliminary resultsRoutine
4 Aug 2025Q2 2025 preliminary results: H1 revenue KRW 25.29 bn, operating income KRW 3.79 bnBaseline for 2026 comparisons
6 Aug 2025Harim MOU on variant IB vaccinesIntegrator partnership in poultry
25 Sep 2025APQA ASF vaccine experts' seminar; CAVAC and Avinext present; bait-vaccine work in VietnamProgramme visibility
30 Oct 2025Board approves KRW 1.0 bn treasury-share purchaseCapital return
3 Nov 2025Q3 2025 preliminary results: revenue KRW 10.98 bn (+2.4% YoY), operating income KRW 1.55 bn (-9.5% YoY)Margin pressure
3 Nov 2025 – 30 Jan 2026Buyback carried out: 101,906 shares (97.7% of plan)Capital return
10 Dec 2025Board approves KRW 2.0 bn treasury-share cancellationPermanent reduction in share count
Feb 2026FowlShot ND Max launchedPoultry line extension
6 Feb 2026Cash dividend of KRW 200 per share (total about KRW 1.9 bn; +17.6% DPS)Third consecutive DPS increase
25 Feb 2026ASF vaccine results presentation; 2027 commercialisation target; field trials in Vietnam and the PhilippinesPipeline milestone
16 Mar 2026FY2025 business report filed: revenue KRW 49.1 bn, operating income KRW 6.5 bn, net income KRW 6.2 bnAnnual disclosure
25 Mar 2026Corporate value-up plan disclosure; high-dividend company statusGovernance and tax benefit for shareholders
15 Apr 2026SuiShot ASF-X export licence from APQAMajor pipeline de-risking event
17 Apr 2026Company press release on ASF-X export plansInvestor communication
Apr 2026K-FMD clinical trial plan approved (with Optipharm)Second pipeline option
6 May 2026Q1 2026 preliminary results: Q1 revenue about KRW 12.6 bn, operating income about KRW 3.0 bn (derived)Strong start to the year
16–19 Jun 2026IPVS 2026 Ho Chi Minh City: ASF-X field-trial data; registration expected within monthsInternational validation
22 Jun 2026APQA opens a government BL3 suite for commercial ASF vaccine production (pilot)Industry enabler; primarily used by peer Komipharm
25 Jun 2026CapriShot CLA goat vaccine licensedNew species segment
25 Jun 2026Board approves KRW 2.1 bn treasury-share cancellationCapital return
8 Jul 2026KRW 5.81 bn SAT1 FMD vaccine supply contract with PPS (11.85% of FY2025 revenue; runs to 7 Nov 2026)Material H2 2026 revenue contribution; supplied by importing from overseas manufacturers
27 Jul 2026Trade-press feature on FowlShot protection against K-IId QX IBPoultry franchise
5 Aug 2026Q2 2026 preliminary results: revenue KRW 11.90 bn (-1.2%), operating income KRW 1.14 bn (-23.8%), net income KRW 1.29 bn (+90.4%)Operating softness offset by non-operating gains
6 Aug 2026Report on securities ownership by officers and major shareholders–
14 Aug 2026H1 2026 semi-annual report filedPeriodic disclosure
18 Aug 2026Liquidity provider contract signedMeasure to support trading liquidity in a thinly traded stock
26 Aug 2026Board of Audit and Inspection publicises its pre-consulting that enabled the BL3 opening for ASF vaccine productionPolicy support for the industry

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Region (%): Export share of revenue rose from 13% in FY2016 to 27.2% in FY2018.
Choong Ang Vaccine Laboratory Co., Ltd. — Revenue by Region (%)
Series (%)FY2016FY2018
Export share of revenue1327.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. 1ETF Shopping — company page (DART FY2021–FY2025 business reports): — Employees, ownership, investees, officer pay averages (etfshopping.com)
  2. 2ETF Shopping — dividend page: — DPS history, payouts, buyback and cancellation filings, value-up disclosure (etfshopping.com)
  3. 3ETF Shopping — stock page: — Revenue and operating income history FY2016–FY2025 (etfshopping.com)
  4. 4ETF Shopping — earnings page: — Results-disclosure dates (etfshopping.com)
  5. 5Butler: — FY2021–FY2025 revenue, operating and net income; Q2 2026 product mix; recent filings (butler.works)
  6. 6ValueLine — balance sheet, income statement, cash flow, summary: (and /income, /cashflow, /summary) — Detailed financial line items, multiples, company overview (valueline.co.kr)
  7. 7FY2024 AGM results filing (25 Mar 2025), via FinancialReports.eu: — FY2024 audited totals, EPS, dividend, director biographies (financialreports.eu)
  8. 8Kormedi (5 Aug 2026): — Q2 and H1 2026 results; FY2025 standalone summary (kormedi.com)
  9. 9BioBook Media: — Explanation of Q2 2026 net income; 60% export target; 20+ countries (biobookmedia.com)
  10. 10Edaily (8 Jul 2026): — SAT1 PPS contract (en.edaily.co.kr)
  11. 11Edaily (9 Jul 2026): — SAT1 import model; stockpile plan (en.edaily.co.kr)
  12. 12Edaily (Nov 2025): — Q3 2025 results (edaily.co.kr)
  13. 13DailyVet — ASF export licences: — ASF-X licence, label, Vietnam contract manufacturing (dailyvet.co.kr)
  14. 14DailyVet — ASF results presentation (Feb 2026): — 2027 target; field trials; management comments (dailyvet.co.kr)
  15. 15DailyVet — K-FMD clinical trial: — K-FMD programme (dailyvet.co.kr)
  16. 16DailyVet — goat CLA vaccine: — CapriShot CLA (dailyvet.co.kr)
  17. 17DailyVet — BL3 opening: — APQA BL3 pilot (dailyvet.co.kr)
  18. 18PigPeople — Board of Audit pre-consulting: — BL3 opening used by Komipharm (pigpeople.net)
  19. 19DailyVet — Harim MOU: — Harim partnership (dailyvet.co.kr)
  20. 20DailyVet — Circo-ONE China launch: and — China registration and Elanco agreement: dailyvet.co.kr · dailyvet.co.kr
  21. 21DailyVet — tag archives (FowlShot, Circo-ONE): — Poultry launches; Brazil shipment date (dailyvet.co.kr)
  22. 22DailyVet — Y280 products: and — Y280 combination vaccines; CAvant: dailyvet.co.kr · dailyvet.co.kr
  23. 23DailyVet — IHS Markit award: — 2020 award; product highlights (dailyvet.co.kr)
  24. 24DailyVet — founder biography: — Founding history (dailyvet.co.kr)
  25. 25DailyVet — Gyeongsang National University donation: — Nonsan plant; product count (dailyvet.co.kr)
  26. 26DailyVet — Chungbuk National University MOU: — 2021 MOU (dailyvet.co.kr)
  27. 27Food & Agribusiness World (IPVS 2026): — Field-trial results; registration expectations (foodagribusiness.world)
  28. 28PigPeople — K-FMD IND: — FMD import dependence (pigpeople.net)
  29. 29PigPeople — ASFV-MEC-01 paper: — Publication; PCT filing (pigpeople.net)
  30. 30NICE Technology Analysis Report (Oct 2019): — FY2018 R&D, capacity, channel mix (ssl.pstatic.net)
  31. 31eToday (2023): — Product count, about 10% R&D claim, main export markets, PED-X (etoday.co.kr)
  32. 32NewsPim (Aug 2016): — Export share; domestic market structure (m.newspim.com)
  33. 33NewsTomato (Aug 2010): — 2009 market share (newstomato.com)
  34. 34FN News (Feb 2007): — Early history; 2007 market share (fnnews.com)
  35. 35Company deck (via PCU): — Founding and listing dates; facilities; vision (pcu.ac.kr)
  36. 36ThaiPR / PR Newswire (2021): — Export countries; KVGMP facilities (thaipr.net)
  37. 37StockHub: — 52-week range; analyst coverage; buyback execution (stockhub.kr)
  38. 38Morningstar AU: — Classification; alternative employee count (morningstar.com.au)
  39. 39PharmaShots — Top 20 Animal Health Companies 2025: — Global market size; multinational revenue (pharmashots.com)
  40. 40Tribune India / Reuters (WOAH on Vietnamese ASF vaccines): — Regulatory context for ASF (tribuneindia.com)
  41. 41Asia Economy (Woogene B&G CLA patent): — Goat CLA competitor (core.asiae.co.kr)
  42. 42eToday (Daesung Microbiological Labs): — Peer profile (etoday.co.kr)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.